Trade

with

Enanta Pharmaceuticals Inc
(NASDAQ: ENTA)
AdChoices
46.59
+3.01
+6.91%
After Hours :
45.78
-0.81
-1.74%

Open

43.71

Previous Close

43.58

Volume (Avg)

566.57k (236.07k)

Day's Range

43.46-47.00

52Wk Range

18.31-47.00

Market Cap.

809.83M

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

18.58M

P/E Ratio (EPS)

23.47 (1.86)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 32.05M

    • Net Income

    • 9.63M

    • Market Cap.

    • 809.83M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 75.42

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -

    • Price/Sales

    • 18.94

    • Price/Book Value

    • 5.66

    • Price/Cash flow

    • 36.36

      • EBITDA

      • 9.88M

      • Return on Capital %

      • 25.10

      • Return on Equity %

      • 26.21

      • Return on Assets %

      • 25.10

      • Book Value/Share

      • 8.23

      • Shares Outstanding

      • 18.58M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 2,450.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -55.00

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • 42.87

            • 39.38

            • Net Profit Margin

            • 75.42

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 26.17

              • 2.92

              • Quick Ratio

              • 23.09

              • 2.35

              • Interest Coverage

              • 906.23

              • 38.02

              • Leverage Ratio

              • 1.04

              • 2.21

              • Book Value/Share

              • 8.23

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 23.47

                • 238.10

                • P/E Ratio 5-Year High

                • 25.02

                • 634.30

                • P/E Ratio 5-Year Low

                • 7.71

                • 124.82

                • Price/Sales Ratio

                • 17.70

                • 8.94

                • Price/Book Value

                • 5.29

                • 8.12

                • Price/Cash Flow Ratio

                • 36.36

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 26.21

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 25.10

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 26.23

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 796.30k

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.33

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  9.03M
                  Operating Margin
                  28.17
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  36.36
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  85.39%

                  Mutual Fund Ownership

                  24.55%

                  Float

                  70.61%

                  5% / Insider Ownership

                  4.82%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    923,566

                  • 0.00

                  • 4.97

                  • Eagle Small Cap Growth Fund

                  •  

                    627,756

                  • 9.40

                  • 3.38

                  • Fidelity VIP Growth Portfolio

                  •  

                    397,280

                  • 0.00

                  • 2.14

                  • Fidelity Advisor® Equity Growth Fund

                  •  

                    227,756

                  • 0.00

                  • 1.23

                  • Glenmede Small Cap Equity Portfolio

                  •  

                    193,460

                  • 38.99

                  • 1.04

                  • iShares Russell 2000 (AU)

                  •  

                    163,317

                  • -1.00

                  • 0.97

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    140,822

                  • 0.00

                  • 0.76

                  • Ivy Micro Cap Growth Fund

                  •  

                    120,500

                  • 5.98

                  • 0.65

                  • Fidelity® Growth Discovery Fund

                  •  

                    105,984

                  • 0.00

                  • 0.57

                  • Vanguard Total Stock Mkt Idx

                  •  

                    97,279

                  • 0.00

                  • 0.52

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    2,003,208

                  • -18.82%

                  • 10.78

                  • Consonance Capital Management LP

                  •  

                    1,546,097

                  • +23.25%

                  • 8.32

                  • RA Capital Management, LLC

                  •  

                    1,539,586

                  • -0.10%

                  • 8.29

                  • Eagle Asset Management, Inc.

                  •  

                    925,873

                  • +15.39%

                  • 4.98

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  -

                  Enanta Pharmaceuticals Inc , was incorporated in Delaware in 1995. The Company is a research and development focused biotechnology group y that uses its chemistry-driven approach and drug discovery capabilities to create small molecu...morele drugs in the infectious disease field. The Company is developing novel protease, NS5A, cyclophilin and nucleotide polymerase inhibitors targeted against the hepatitis C virus (“HCV”). Additionally, it has created a new class of macrolide antibiotics known as Bicyclolides that overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community Methicillin-resistant Staphylococcus aureus (“MRSA”). The Company manages its operations as a single segment for the purposes o...moref assessing performance and making operating decisions. The Company is a biotechnology company focused on discovering and developing small molecule drugs in the infectious disease field. It has competition from large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are commercializing or pursuing the development of products that target viral diseases, including the same diseases we are targeting.lessless

                  Key People

                  Dr. Jay R. Luly

                  CEO/Director/President

                  Mr. Paul J. Mellett

                  CFO/Chief Accounting Officer/Senior VP, Divisional

                  Dr. Bruce L.A. Carter,PhD

                  Director

                  George Golumbeski

                  Director

                  Dr. Ernst-Gunter Afting,PhD,M.D.

                  Director

                  • Enanta Pharmaceuticals Inc

                  • 500 Arsenal Street

                  • Watertown, MA 02472

                  • USA.Map

                  • Phone: +1 617 607-0800

                  • Fax: +1 617 607-0530

                  • enanta.com

                  Incorporated

                  1995

                  Employees

                  44

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: